NSE: ZYDUSLIFE | BSE: 532321

Mid-range Performer

Download real time

969.30 1.65 (0.17%)

26.81% Fall from 52W High

971.3K NSE+BSE Volume

NSE 16 Jul, 2025 3:12 PM (IST)

97,534.3

Market Cap

High in industry

0.8

Beta 1Year

Very Low volatility

US FDA Approval

Zydus Lifesciences receives US FDA approval for Celecoxib Capsules, with a market size of $122.6 mn See details

Zydus Lifesciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ZYDUSLIFE, BSE:532321 Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd.

23 Jun 2020

969.30

0.17%

CADILA HEALTHCARE LT..

Buy: Zydus Lifesciences Ltd.

Rudra Shares and Stock Brokers Ltd

Cadila Healthcare has emerged at the forefront of India's battle to fight against COVID-19. Company is one of the world's largest producer of anti-malarial drug hydroxychloroquine which is widely used as a prophylactic drug to prevent COVID-19 infections. Apart from that, to offer treatment options for COVID 19, company is now exploring multiple options from its portfolio of biological products and based on the available evidence, has selected the long-acting biological therapy, Pegylated Interferon alpha-2b as a potential treatment. It may be noted that Zydus Cadila has been commercially manufacturing Pegylated Interferon Alpha-2b under the...

Zydus Lifesciences Ltd. is trading below its 30 day SMA of 974.2

Zydus Lifesciences Ltd.

22 Jun 2020

969.30

0.17%

Q4FY20 Result Update - US(Gx) and OTC led earnings surprise - Upgrade to 'REDUCE'

Sell: Zydus Lifesciences Ltd.

Recommendation Target

Prabhudas Lilladhar

Q4FY20 earnings were higher than our estimate considering 1) US growth of 5% QoQ (PLe 7% decline QoQ) due to stock-up and seasonality effect of Tamiflu 2) Consumer Wellness reported a growth of 21% YoY, while adjusted growth would have been 10%YoY. We change our rating to REDUCE (earlier SELL) and derive a new TP of Rs329 (Rs263) based on 18x PE (earlier 15x) of FY22E. We upgrade CDH on the back of 1) improved guidance for US market led by new products 2) biosimilar launch in India and EM's 3) resolution of...

Zydus Lifesciences Ltd.'s price crossed above 30Day SMA today

Zydus Lifesciences Ltd.

22 Jun 2020

969.30

0.17%

Cadila Healthcare Ltd

Buy: Zydus Lifesciences Ltd.

Target

Karvy

Valuation and Risks: We reduce our Revenues for FY21E / FY22E by 1.6% / 2.5% due to downgrade across revenue segments with the exception of US and EU.

Zydus Lifesciences Ltd.'s price crossed above 30Day SMA today

Zydus Lifesciences Ltd.

22 Jun 2020

969.30

0.17%

Cadila Healthcare Limited

Buy: Zydus Lifesciences Ltd.

Recommendation Target

ICICI Securities Limited

US (44% of revenues) grew at ~12% CAGR in FY16-20 backed by aggressive filings, product launches. Launches of authorised generics also contributed to overall growth. US pipeline (cumulative) consists of 390 filed ANDAs, 99 pending final approvals. However, resurfacing of cGMP issues at Moraiya and an imminent slowdown in base are main near term headwinds. We expect US sales to grow at ~9.5% CAGR in FY20-22E to | 7502 crore. Our growth assumptions model near term Hydroxychloroquine opportunity in the US but besides this no significant meaningful launches....

Zydus Lifesciences Ltd. is trading below its 30 day SMA of 974.2

Zydus Lifesciences Ltd.

20 Jun 2020

969.30

0.17%

Lower operating/financial leverage outweighs product mix benefit

Buy: Zydus Lifesciences Ltd.

Target

Motilal Oswal

20 June 2020 by regrouping it into the Mass and Specialty segments and b) differentiated launches in US Generics. We maintain our EPS estimates for FY21/FY22E and continue to value CDH at 21x 12M forward earnings to arrive at TP of INR420. We remain positive on CDH on account of better prospects in DF (encouraged by changed strategy), a healthy ANDA pipeline (including injectables and transdermals) in the US market, and regulatory works at Moraiya nearing completion. Maintain Buy. CDHs sales at INR37.5b (in-line) for 4QFY20 stood largely flat YoY. US sales (47% of sales) fell 1.9% YoY to INR17.6b. The India Branded Formulations business (24% of sales) was INR8.9b, almost flat YoY. EM and LATAM (5% of sales) revenue was down 17% YoY to INR1.7b, while API registered strong growth of 21% YoY, with sales of INR1.2b. The Consumer Wellness business grew 21.

Zydus Lifesciences L.. has an average target of 988.60 from 5 brokers.

Zydus Lifesciences Ltd.

19 Jun 2020

969.30

0.17%

Cadila Health

Hold: Zydus Lifesciences Ltd.

Target

Sharekhan

The Q4FY20 results of Cadila Healthcare Limited (Cadila) were a mixed bag and reflected the impact of Covid-19. The sales at Rs 3752 cr were flat on a y-o-y basis, but missed estimates. Revenues amounting to Rs 250 cr were deferred due to supply chain / logistics issues, which the management expects to recoup in the current quarter. The gross margins for the quarter improved by 350 bps y-o-y but an increase in the employee cost and higher other expenses wiped out the gains, leading to a 60 bps y-o-y contraction in Operating Margins. OPM's stood at 21.1% while operating profit stood at Rs 791 crdeclining by 2.4% y-o-y,...

Zydus Lifesciences Ltd. is trading below its 30 day SMA of 974.2

Zydus Lifesciences Ltd.

20 Apr 2020

969.30

0.17%

Cadila Healthcare Limited

Hold: Zydus Lifesciences Ltd.

Target

ICICI Securities Limited

On the business front, despite the nationwide lockdown, domestic growth is expected to remain more or less stable. Exports growth, barring for one or two months due to congestion in all major ports globally, is also expected to remain strong due to 1) currency benefit, 2) slowdown in competition due to delay in new approvals that will be beneficial for existing players and 3) expected demand continuum across the world despite Covid-19. Some windfall is also expected in some critical productsa case in point is Hydroxychloroquine, a malaria drug that is likely to be repurposed as a prophylaxis for Covid-19 treatment in some cases....

Zydus Lifesciences L.. has an average target of 988.60 from 5 brokers.

Zydus Lifesciences Ltd.

07 Apr 2020

969.30

0.17%

Cadila Healthcare Ltd: Pharmaceuticals

Buy: Zydus Lifesciences Ltd.

Target

Karvy

Cadila Heathcare (Cadila HC) post its reorganization and productivity initiatives indomestic formulations space

Zydus Lifesciences L.. has an average target of 988.60 from 5 brokers.

Zydus Lifesciences Ltd.

13 Feb 2020

969.30

0.17%

CADILA HEALTH CARE LIMITED

Hold: Zydus Lifesciences Ltd.

Target

Geojit BNP Paribas

Cadila Healthcare is India's leading vertically integrated pharmaceutical company. With its presence across the value chain, it manufactures finished dosage forms, active pharmaceutical ingredients, animal healthcare...

Zydus Lifesciences Ltd. is trading above its 200 day SMA of 951.7

Zydus Lifesciences Ltd.

10 Feb 2020

969.30

0.17%

Cadila Healthcare Limited

Hold: Zydus Lifesciences Ltd.

Target

ICICI Securities Limited

Q3FY20 revenues grew 1.7% YoY to | 3638.1 crore (I-direct estimate: | 3439.7 crore). Consolidation of Craft Portfolio was largely offset by 13.4% YoY decline in the US to | 1675.3 crore. Domestic formulations grew 7.6% YoY to | 910.3 crore. EBITDA margins contracted 441 bps YoY to 19.1% (Idirect estimate: 18.8%), mainly on account of higher employee and other expenditure. EBITDA de-grew 17.4% YoY to | 693.2 crore (I-direct estimate: | 646.7 crore). PAT de-grew 26.5% YoY to | 375.2 crore (I-direct estimates:...

Zydus Lifesciences Ltd.'s price crossed above 30Day SMA today

Is Cadila Healthcare Ltd. worth buying?

851 Votes:

Buy 82.02%

Sell 9.87%

Hold 8.11%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf